1378388-16-9

Basic information

• Product Name: (2S,4S)-1-(tert-butoxycarbonyl)-4-(MethoxyMethyl)pyrrolidine-2-carboxylic acid
• Synonyms: (2S,4S)-1-(tert-butoxycarbonyl)-4-(MethoxyMethyl)pyrrolidine-2-carboxylic acid;(2S,4S)-4-(Methoxymethyl)-1,2-pyrrolidinedicarboxylic acid 1-(1,1-dimethylethyl) ester;GS-5816 interMediate;3-(2-bromoacetyl)-10,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)-one;(2S,4S)-1-(tert-butoxycarbonyl)-4-(MethoxyMethyl);(2s,4s)-4-(methoxymethyl)-1,2-pyrrolidinedicarboxylic acid;Velpatasvir Intermediate 3;N-Tert-Butoxycarbonyl-(4S)-4-Methoxymethyl-L-proline
• CAS NO: 1378388-16-9
• Molecular Formula: C₁₂H₂₁NO₅
• Molecular Weight: 259.29884
• EINECS: 1312995-182-4
• Mol File: 1378388-16-9.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 371.2±27.0 °C(Predicted)
• Appearance: /
• Density: 1.162±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 3.91±0.40(Predicted)
• Water Solubility: 12.2g/L
• CAS DataBase Reference: (2S,4S)-1-(tert-butoxycarbonyl)-4-(MethoxyMethyl)pyrrolidine-2-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,4S)-1-(tert-butoxycarbonyl)-4-(MethoxyMethyl)pyrrolidine-2-carboxylic acid(1378388-16-9)
• EPA Substance Registry System: (2S,4S)-1-(tert-butoxycarbonyl)-4-(MethoxyMethyl)pyrrolidine-2-carboxylic acid(1378388-16-9)

Safety Data

• Hazardous Substances Data: 1378388-16-9(Hazardous Substances Data)

Usage

General Description

(2S,4S)-1-(tert-butoxycarbonyl)-4-(MethoxyMethyl)pyrrolidine-2-carboxylic acid is a chemical compound with a molecular formula of C13H23NO5. It is a pyrrolidine derivative with a tert-butoxycarbonyl protective group on the nitrogen atom and a methoxymethyl functional group on the fourth carbon atom. (2S,4S)-1-(tert-butoxycarbonyl)-4-(MethoxyMethyl)pyrrolidine-2-carboxylic acid is often used in synthetic chemistry as a building block for the creation of more complex molecules. It has potential applications in medicinal chemistry, particularly in the development of pharmaceutical drugs. Additionally, it may also exhibit biological activity or serve as a precursor for the synthesis of other compounds with useful properties. Overall, this compound has significant relevance in the field of organic chemistry and drug discovery.

Upstream product

• 74844-91-0 1-tert-butyl 2-methyl (2S,4R)-4-hydroxy-1,2-pyrrolidinedicarboxylate 
• 170850-75-6 BOC-Hyp-OtBu 
• 64750-03-4 (2S,4S)-pyrrolidine-2,4-dicarboxylic acid dimethyl ester 
• 13726-69-7 (2S,4R)-4-hydroxy-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid 
• 51-35-4 4R-4-hydroxyproline 
• 686766-82-5 (2S,4S)-N-tert-butoxycarbonyl-2-tert-butoxycarbonyl-4-carboxyl pyrrolidine 
• 74-88-4 methyl iodide 
• 1378393-23-7 C₁₅H₂₃NO₈ 

Downstream Products

• 1256390-88-1 (2S,4S)-tert-butyl 2-(4-(4-bromophenyl)-1H-imidazol-2-yl)-4-(methoxymethyl)pyrrolidine-1-carboxylate 
• 1378391-42-4 (2S,4S)-2-(2-(9-bromo-8-oxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromen-3-yl)-2-oxoethyl) 1-tert-butyl 4-(methoxymethyl)pyrrolidine-1,2-dicarboxylate 
• 1378391-43-5 (2R,4R)-1-tert-butyl 2-(2-(9-((2S,5S)-1-((S)-2-(methoxycarbonylamino)-3-methylbutanoyl)-5-methylpyrrolidine-2-carbonyloxy)-8-oxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromen-3-yl)-2-oxoethyl) 4-(methoxymethyl)pyrrolidine-1,2-dicarboxylate 
• 1378391-44-6 tert-butyl (2S,4S)-2-[5-(2-{(2S,5S)-1-[N-(methoxycarbonyl)-L-valyl]-5-methylpyrrolidin-2-yl}-1,4,5,11-tetrahydroisochromeno[4′,3′:6,7]naphtho[1,2-d]imidazol-9-yl)-1H-imidazol-2-yl]-4-(methoxymethyl)pyrrolidine-1-carboxylate 
• 1378391-45-7 tert-butyl (2S,4S)-2-[5-(2-{(2S,5S)-1-[N-(methoxycarbonyl)-L-valyl]-5-methylpyrrolidin-2-yl}-1,11-dihydroisochromeno[4′,3′:6,7]naphtho[1,2-d]imidazol-9-yl)-1H-imidazol-2-yl]-4-(methoxymethyl)pyrrolidine-1-carboxylate 
• 1377604-63-1 methyl {(1R)-2-[(2S,4S)-2-(5-{2-[(2S,5S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-5-methylpyrrolidin-2-yl]-1,4,5,11-tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-9-yl}-1H-imidazol-2-yl)-4-(methoxymethyl)pyrrolidin-1-yl]-2-oxo-1-phenylethyl}carbamate 
• 1377049-84-7 methyl {(2S)-1-[(2S,5S)-2-(9-{2-[(2S,4S)-1-{(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyl}-4-(methoxymethyl)pyrrolidin-2-yl]-1H-imidazol-5-yl}-1,11-dihydroisochromeno[4′,3′:6,7]naphtho[1,2-d]imidazol-2-yl)-5-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate 
• 1378391-86-6 (2S,4S)-tert-butyl 2-(5-iodo-1H-imidazol-2-yl)-4-(methoxymethyl)pyrrolidine-1-carboxylate 
• 1844064-96-5 (2S,4S)-2-[5-(2-{(2S,4S)-1-{N-(methoxycarbonyl)-L-valyl}-5-methylpyrrolidin-2-yl}-1,11-dihydroisochromene[4',3':6,7]naphtho[1,2-d]imidazol-9-yl)-1H-imidazol-2-yl]-4-(methoxymethyl)pyrrolidine 

Relevant articles and documents

A antiviral drug intermediate resolution method

The invention relates to a method for splitting an antiviral drug intermediate, and particularly relates to a method for splitting (2S)-1-(t-butyloxycarboryl)-4-(methoxymethyl)-pyrrolidine-2-carboxylic acid. According to the method, (2S,4S)-1-(t-butyloxyc

Compound used for inhibiting hepatitis C virus, and pharmaceutical applications thereof

The invention relates to a compound which is represented by formula I, is used for inhibiting hepatitis C virus, and possesses excellent bioavailability, and a nontoxic pharmaceutically acceptable salt thereof. The compound possesses extremely high inhibition effect on HCV of all genotypes. In the formula I, R is used for representing hydrogen atom, glycyl, L-alanyl, L-leucyl, L-valyl, or L-isoleucyl.

Preparation method of anti-virus drug intermediate

The invention discloses a preparation method of an anti-virus drug intermediate. A structure of the intermediate corresponds to a formula V: the formula V is shown in the description. The method comprises the following steps: carrying out reaction in four steps: condensation, reduction, dissociation and splitting on a compound (2S)-N-Boc-4-methoxymethylene pyrrolidine-2-carboxylic acid used as a raw material to finally obtain a (4S)-N-Boc-methoxymethyl-L-proline shown in the formula V. The method disclosed by the invention has cheap and easily-available raw materials, reaction conditions are mild, the selective problem is avoided, the yield is higher, and the method is more suitable for industrial production. The preparation method provided by the invention is high in asymmetric hydrogenation selectivity, simple in splitting conditions, mild in reaction conditions, higher in yield, and suitable for industrial amplified production.